Marshall Wace, LLP Global Blood Therapeutics, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$32.4 - $68.18 $54,399 - $114,474	1,679 Added 1.65%	103,490 $7.05 Million
Q2 2022 Aug 15, 2022	BUY	$22.3 - $37.39 $2.27 Million - $3.81 Million	101,811 New	101,811 $3.25 Million
Q1 2022 May 16, 2022	SELL	$25.68 - $35.59 $2.06 Million - $2.85 Million	-80,042 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $1.26 Million - $2.04 Million	50,735 Added 173.12%	80,042 $2.34 Million
Q3 2021 Nov 15, 2021	BUY	$25.48 - $37.34 $746,742 - $1.09 Million	29,307 New	29,307 $747,000
Q4 2020 Feb 16, 2021	SELL	$37.65 - $63.77 $5.04 Million - $8.54 Million	-133,872 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$52.76 - $74.49 $4.64 Million - $6.55 Million	-87,914 Reduced 39.64%	133,872 $7.38 Million
Q2 2020 Aug 13, 2020	BUY	$48.73 - $81.82 $10.8 Million - $18.1 Million	221,786 New	221,786 $14 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.